Date Prepared: October 7, 2010 I GENERAL INFORMATION. Name: J. Peter Oettgen Office Address: Beth Israel Deaconess Medical Center

330 Brookline Avenue, RN-270D Boston MA 02115

Home Address: 15 Linden Street #5

Brookline, MA 02445 Work Phone: (617)-667-3390 Email: joettgen@caregroup.harvard.edu FAX: (617)-975-5299 or (617)-667-3591 Place of Birth: Nairobi, Kenya Education:

1982 B.A. Biochemistry, (Magna cum laude), Bowdoin College, Brunswick, ME 1987 M.D., University of Connecticut School of Medicine, Farmington, CT

Postdoctoral Training:

Internship and Residency: 1987-1988 Intern in Internal Medicine, New England Medical Center, Boston, MA 1988-1990 Resident in Internal Medicine, New England Medical Center, Boston, MA Fellowships: 1985-1986 Cardiovascular Research Fellow, Children's Hospital, Boston MA 1990-1993 Cardiology Fellow, Beth Israel Hospital, Boston MA

Licensure and Certification:

1990 Massachusetts License #71658 1990 American Board of Internal Medicine 1993 American Board of Internal Medicine, Subspecialty of Cardiovascular

Disease Academic Appointments:

1993-1997 Instructor in Medicine, Harvard Medical School 1998- 2001 Assistant Professor of Medicine, Harvard Medical School 2002- present Associate Professor of Medicine, Harvard Medical School

2

Hospital Appointments:

1993-1996 Associate in Medicine, Beth Israel Hospital, Boston, MA 1996- present Associate in Medicine, Beth Israel Deaconess Medical Center, Boston,

MA Hospital and Health Care Organization Service Responsibility:

1993-1995 Attending Cardiologist, Electrocardiography Laboratory, Beth Israel Hospital, Boston, MA

1993-1996 Attending Cardiologist, Echocardiography Laboratory, Beth Israel Hospital, Boston, MA

1993-1996 Outpatient Preventive Cardiology Subspecialty Practice, Beth Israel Hospital, Boston, MA

1993-1996 Attending Cardiologist, Coronary Care Unit, Beth Israel Hospital, Boston, MA

1996-2001 Attending Cardiologist, Coronary Care Unit, Beth Israel Deaconess Medical Center, Boston, MA

1996-present Outpatient Preventive Cardiology Subspecialty Practice, Beth Israel Deaconess Medical Center, Boston, MA

2001- present Attending Cardiologist, Electrocardiography Laboratory, Beth Israel Deaconess Medical Center

Major Administrative Responsibilities:

1997- present Director, Preventive Cardiology Beth Israel Deaconess Medical Center

2003- 2008 Director, Vascular Biology Seminar Series, Beth Israel Deaconess Medical Center

2003- present Associate Program Director for Basic Research, Cardiovascular Research Training Program for Cardiovascular Research, Beth Israel Deaconess Medical Center.

2004- present Co-Director, NHLBI Program project; “Endothelial Heterogeneity”. 2005-2007 Director of Research, Division of Vascular and Molecular Medicine , Beth Israel

Deaconess Medical Center 2005-present Chairman, Center for Vascular Biology Research Annual Retreat 2008- present Associate Chief, Division of Molecular and Vascular Medicine, Beth Israel

Deaconess Medical Center 2008-2010 Special Advisor in Vascular Biology and Hypertension, NIH/NHLBI (Bethesda, MD)

Major Committee Assignments:

1999-present Internal Medicine Residency Selection Committee BIDMC 1997-present Member, Cardiovascular Data Analysis Center (CDAC), Clinical Events

Committee 1998- 2000 Ad hoc Reviewer, NIH Pathology A study section 2001-2002 Regional Co-chairman; Emerging Science in Lipid Management, Chicago, IL 2001-2004 Member, Scientific Board, Sarnoff Endowment for Cardiovascular Research. 2003-present Member, Executive Committee for Vascular Biology Research, BIDMC 2003-present Director, Vascular Biology Research Seminar Series at BIDMC

3

2003 Chairman, NIH/NHLBI Special Emphasis Panel on C-reactive protein 2003-2006 Reviewer, American Heart Association Vascular Wall Biology Study Group 1 2004-present Co-Director NIH/NHLBI PPG “Endothelial Phenotypes in Health and Disease” 2005, 2006 Reviewer, Special Emphasis Panel on Nanotechnology and Cardiovascular disease

NIH/NHLBI 2005-2006 Co-Chairman, Emerging Science in Lipid Management, Mid-Atlantic Regional

Working Group 2005-2006 Chairman, Vascular Biology Junior Faculty Search Committee 2005-present Director of Research, Division of Molecular and Vascular Medicine, BIDMC 2006 Reviewer, NHLBI Exploratory Programs in Systems Biology 2006-2007 Co-Chairman, American Heart Association Vascular Wall Biology Study Group 1

2006 NIH-NHLBI Strategic Planning Committee “Vascular Diseases and Hypertension” 2007-2008 Chairman, American Heart Association Vascular Wall Biology Study Group 1 2009 Member, AHA National Science Classification Task Force Committee Professional Societies:

1990- present Member, Massachusetts Medical Association 1993- present Member, American College of Cardiology - Fellow 1993- present Member, American Heart Association 1999- present Member, Society for Developmental Biology 1999- present Member, Federation of American Societies for Experimental Biology 2000- present Member, American Association for the Advancement of Science

Grant Review Activities:

1998-2000 Ad hoc Reviewer, NIH Pathology A study section 2003 Chairman, NIH/NHLBI Special Emphasis Panel on C-reactive protein 2003-2006 Reviewer, American Heart Association Vascular Wall Biology Study Group 1 2005, 2006 Reviewer, Special Emphasis Panel on Nanotechnology and Cardiovascular Disease

NIH/NHLBI 2006 Reviewer, NHLBI Exploratory Programs in Systems Biology 2006-2007 Co-Chairman, American Heart Association Vascular Wall Biology Study Group 1 2007-2008 Chairman, American Heart Association Vascular Wall Biology Study Group 1

Editorial Boards: Ad-hoc:

2001-present Reviewer for American Journal of Physiology 2002-present Reviewer for Journal of Biological Chemistry 2003-present Reviewer for Arthritis and Rheumatism 2004-present Reviewer for Magnetic Resonance Medicine 2004-present Reviewer for Circulation Research 2005-present Reviewer for Molecular and Cellular Cardiology 2006-present Reviewer for Journal of Vascular Research 2006-present Reviewer for Arteriosclerosis and Thrombosis Research 2006-present Reviewer for Circulation 2006-present Reviewer for American Journal of Respiratory Cell and Molecular Biology 2007-present Reviewer for Journal of Clinical Investigation 2008-present Reviewer for Journal of Hemostasis and Thrombosis 2008-present Reviewer for Blood

4

Awards and Honors:

1983 Sigma Xi Speaker-University of Connecticut Medical School 1984 Garcelon-Merit Medical School Scholarship 1985-1986 Grant from the Sarnoff Endowment for Cardiovascular Science 1991-1993 National Research Service Award 1995-2000 NIH Physician Scientist Award (K08) 1997-1998 Beth Israel Deaconess Medical Center Young Investigator Award 2001-2002 Enterprise Award: Beth Israel Deaconess Medical Center 2007-2012 American Heart Association Established Investigator Award

II RESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS. A. Funding Information.

Past Funding: 1985-1986 Sarnoff Endowment for Cardiovascular Science, Principal Investigator, Genomic

Structure and identification of RFLP Markers in the ApoAI-CIII-AIV gene cluster. 1991-1993 NIH (NRSA), Principal Investigator, The role of oxidized LDL in cytokine gene

activation during atherosclerosis. 1997-1998 BIDMC Young Investigator Award, Principal Investigator, Identification of novel

transcriptional methods of vasculogenesis 1996-2001 Physician Scientist Award (KO8); NIH/NCI 1. The Role of ESE-1 in Vascular Inflammation.” Principal Investigator: J. Peter Oettgen, M.D. Agency: NIH/NHLBI $200,000/year direct costs. Period: July, 2001-2006

2. Type:RO1 (HL67219-01 , years 1-4) Period: September, 2001-August, 2005 "The Role of the Ets Factor NERF in Vasculogenesis" Principal Investigator: J. Peter Oettgen, M.D. Agency: NIH/NHLBI $201,468/year direct costs.

3. Type: RO1(HL63008-01, years 1-4) Period: September, 1999-August, 2003 “Identification of Novel Regulators of Angiogenesis.” Principal Investigator: Peter Oettgen Agency: Johnson and Johnson Type: Industry support (December 2000 – 2003)

$70,000/yr

4. “The Role of Angiopoietin-1 in Rheumatoid Arthritis” Principal Investigator: J. Peter Oettgen MD Agency NIH/NIAMS $165,000/year direct cost Type: RO1: (AR-47592-01) Period September 2002-August 2008

5

5. “Structure-based in silico Screen for Small Molecule Inhibitors of Ets-1 Activity” Role: Co-Investigator, Principal Investigator: Alan Rigby

Agency: NIH/NIAMS $150,000/yr Type R21 (AR-054442-01) Period: June 2007-July 2009

6. “Molecular Mechanisms of Endothelial Differentiation” Principal Investigator: J. Peter Oettgen M.D. (Project 2 of PPG) Agency: NIH/NHLBI $220,000/yr direct cost Type: PO1 (HL76540-01) P.I. Aird July 2004- June 2010. 7. “Stem Cell Core” Principal Investigator: J. Peter Oettgen M.D. $70,000/year direct costs

Type: PPG Core PO1 (HL76540-01) P.I. Aird July 2004- June 2010.

Current Funding: 1. “Transcriptional Regulation of ” Principal Investigator: J. Peter Oettgen M.D. (Project 2 of PPG) Agency: NIH/NHLBI $250,000/yr direct cost Type: PO1 (HL76540-06) P.I. Aird July 2010- June 2015.

2. “Molecular Mechanisms of Endothelial Differentiation.” Principal Investigator: Peter Oettgen MD $100,000/year direct costs Type: American Heart Association Established Investigator Award Jan 2007 –Dec 2012 3. “The Role of Ets-1 in Vascular Inflammation” Principal Investigator: J. Peter Oettgen M.D. NIH/NHLBI “The Role of Ets-1 in Vascular Inflammation” $266,000/year direct costs

Type: R01 (HL082717) 09/01/08-08/31/12

B. Report of Current Research Activities

1. Bench Research

1. “Role of the Ets Factor NERF in B Cell Function” (Principal Investigator) The purpose of this project is to identify the role of the Ets transcription factor NERF in regulating the expression of genes involved in B cell function and differentiation. In particular the tyrosine kinase blk has been identified as a NERF target gene.

2. “Role of the Ets Factor NERF in Vasculogenesis” (Principal Investigator)

In addition to its function in B cell function, we have determined a role for NERF in

6

endothelial function and vascular development. This project is designed to determine the role of NERF during vascular development and endothelial differentiation.

3. “Identification of Novel Regulators of Angiogenesis” (Principal Investigator)

We have identified that a subset of Ets factors including NERF and ELF-1 are up-regulated during vascular development. The purpose of this grant is to explore the role of these factors during angiogenesis associated with tumors and other diseases.

4. “The Role of ESE-1 in Vascular Inflammation” (Principal Investigator)

We have determined that the Ets factor ESE-1 although not expressed at baseline in blood vessels, is highly inducible in response to inflammatory cytokines, and is a novel transcriptional mediator of inflammation. The purpose of this project is to further characterize the role of ESE-1 in regulating vascular inflammation.

5. “The Role of Angiopoietin-1 in Rheumatoid Arthritis” (Principal Investigator)

Angiopoietin-1 is a novel angiogenic factor. We have recently determined that Angiopoietin-1 is up-regulated in rheumatoid arthritis. The purpose of this project is to further define the role of Angiopoeitin-1 in inflammatory arthritis.

Report of Teaching and Training: 1. Local Contributions: 1993-1995 EKG Laboratory Attending

Supervise and teach Medical Students 1-2, Cardiology Fellows 1 -2 1 month/year

1993-1996 Echocardiography Staff Attending

Supervise and teach Cardiology Fellows 2-3 1 month/year

1994-2002 Coronary Care Unit Attending

Supervise and teach Cardiology Fellows 1-2, Medical Residents 4-5, Medical Student 1 2 months/year

1993-present Director, Cardiovascular Health and Lipid Center “The Management of Lipid

Disorders and Prevention” Supervise and teach Cardiology Fellows, Endocrine Fellows, Medical Residents in 2-3 days/month

2. Continuing Medical Education Courses 2006-present Harvard Medical School Online CME course

Title: Hyperlipidemia Department of Continuing Education, Harvard Medical School Course Director 50 hours

7

Research Laboratory Trainees: Trainee Post/Pre

Doc Period of training

Current Position or Support

Abdul, Tazeen Pre 1999 Boston University Graduate School

Anshelevich, Aleksandra

Pre 2004-06 UPenn Medical School

Brown, Courtney Pre 2001-04 Univ of Ca, San Francisco, Dept. of Molecular and Cellular Biology

Danilov, Tatyana, MD

Post 2005-05 Yale University Internship

Dube, Antoinise Pre 1996-99 Mass College of Pharmacy

Gaspar, John Pre 1999-03 Albert Einstein College of Medicine

Hiran, Tejindervir, PhD

Post 2002-04 Suffolk Law School

Holmen, Carolina, PhD

Post 2006- Current Research Fellow

Huang, Xuling, MD, PhD

Post 2000-05 Massachusetts General Hospital, Div of Transplant Immunology

Jinadasa, Thara Pre 2006-06 Student

LeBras, Alexandra, PhD

Post 2009-present

Current Research Fellow

Lee, Rebecca Pre 2002-04 Georgetown University Medical School

Li, Sharon Pre 1999 UPenn Medical School

Madore, Rebecca Pre 1999-02 University of Colorado, Graduate Program

Magallon, Jorge C., MD

Post 2005 Instructor in Medicine Beth Israel Deaconess Medical Center, Needham Maynard,

Elizabeth Pre 2003-2008

2003-07

Massachusetts General Hospital School of Occupational Therapy

Ni, Weihua, MD, PhD

Post 2004-06 New Jersey Merck Co.

Nikolova-Krstevski, Vesna, PhD

Post 2006-08 Instructor of Medicine, Dept. of Biochemistry and Molecular Genetics University of New South Wales Sydney Australia Wales, Sydney, Australia

8

Trainee Post/Pre Doc

Period of training

Current Position or Support

Phillips, Ana, PhD Post 2005-05 Boston University School of Medicine, Pathology

Rudders, Susan Pre 1999-00 UPenn Medical School

Vijayaraj, Preethi, PhD

Post 2009-present

Current Research Fellow

Voland, Carole, PhD

Post 2000-02 Inserum, Paris France

Wang, Hong, PhD.

Post 2004-05 Beth Israel Deaconess Medical Center, Hematology/Oncology

Yuan, Lei, PhD, MD

Post 2005-present

Current Research Fellow

Zhan, Yumei, PhD, MD

Post 2002-present

Current Research Fellow

3. Regional, National, or International Contributions:

Local:

1996 Beth Israel Hospital, Primary Care Offices Lexington, MA, Primary Care

Lecture, Primary and Secondary Prevention of Heart Disease.

1997 Speaker, Beth Israel Deaconess Medical Center, West Campus, Boston, MA,

Primary Care Lecture, Management of Lipid Disorders: Effecting Clinical

Outcomes.

1997 Lecturer, Beth Israel Deaconess Medical Center, Internal Medicine CME

Course, Boston MA, Update On Primary and Secondary Prevention of

Coronary Heart Disease.

1999 Speaker, Beth Israel Deaconess Medical Center Internal Medicine Review

Course, Boston, MA, Update on Primary and Secondary Prevention of Heart

Disease.

1999 Speaker, Thorndike Lecture, Beth Israel Deaconess Medical Center, Boston,

MA, Primary and Secondary Prevention of CAD.

9

2000 Speaker, Beth Israel Deaconess Medical Center Internal Medicine Review

Course, Boston, MA Update on Primary and Secondary Prevention of Heart

Disease.

2001 Speaker, Seminars in Vascular Biology, Children’s Hospital, Boston, MA

Identification of Novel Transcriptional Mediators of Vascular Development and

Angiogenesis.

2003 Invited Speaker, Identification of Novel Transcriptional Regulators of Angiogenesis”,

Research Day Beth Israel Deaconess Medical Center Boston

2004 Seminars in Vascular Biology, Harvard Medical School, Angiogenesis and Vascular

Inflammation: Targeting Transcription Factors.

2005 Cardiothoracic Surgery Conference, Beth Israel Deaconess Medical Center

“Cell-based Therapy for Cardiovascular Disease”

2006 Harvard Medical School CME conference. Boston, MA “Update on Treatment of

Hyperlipidemia.”

2006 Harvard Medical School CME conference. Boston, MA “Markers of Vascular

Inflammation.”

2007 Joslin Diabetes Center Symposium on Cardiovascular Disease in Patients with

Diabetes. Speaker “Update on Dyslipidemia in Diabetes Mellitus”

2007 Harvard Stem Cell Initiative Symposium, Boston MA April 30th 2007, “ES cell models

of endothelial differentiation

2009 What’s New Regarding Cardiovascular Risk Factors and Modifiers for Men?” New

Research Building, Harvard Medical School. CME Symposium on Men’s Health

2009 “The Role of ERG as a transcriptional regulator of endothelial differentiation”

Vascular Biology Seminar Series

2009 “A Cardiologist’s perspective of the Vascular Endothelium” Center for Vascular

Biology Summer lecture series

10

2010 “Targeting Transcription Factors in Vascular Inflammation and Remodeling” 2nd

Annual Cardiovascular Institute Retreat, Beth Israel Deaconess Medical Center

2010 “Vascular Endothelium: A Cardiologist’s Viewpoint”

Translational Medicine Series; Center for Vascular Biology Research

2010 “The Role of ERG in Endothelial Differentiation”

Cardiology Research Seminars, Center for Life Sciences, BIDMC

Regional, National, International:

1995 Medical Grand Rounds Glover Hospital, Needham, MA, Lipid management in

the nineties.

1997 Roxbury Health Center, Roxbury, MA, Primary Care Lecture, Current

Management of Lipid Disorders.

1997 Speaker, Mount Auburn Hospital, Cambridge, MA, Cardiovascular Services

Lecture, Multidisciplinary approaches to Primary and Secondary Prevention.

1998 Speaker, Cleveland, OH, Lipid Management in Clinical Practice Diagnosis,

Prevention, and Treatment of Hypertriglyceridemia, Insulin Resistance

Syndrome, and Diabetic Dyslipidemia.

1998 Speaker, Columbus, OH, Lipid Management in Clinical Practice Diagnosis,

Rationale for Cholesterol Lowering.

1998 Speaker, Niagara Falls, Ontario Canada, Lipid Management in Clinical

Practice Diagnosis, Prevention, and Treatment of Hypertriglyceridemia,

Insulin Resistance Syndrome, and Diabetic Dyslipidemia.

1998 Speaker, American Heart Association, Scientific Sessions, Dallas, TX,

Transcriptional Regulation of the Vascular Endothelial Specific Gene, Tie2,

by isoforms of the Ets Factor NERF.

11

1999 Speaker, American Heart Association, Scientific Sessions, Orlando, FL,

Identification of Novel Transcriptional Mediators of Angiogenesis.

2000 Speaker, Cardiac Symposium, Sayre, PA, Preventive Cardiology, Secondary

Prevention and Plaque Stabilization.

2000 Speaker, American Heart Association, Scientific Sessions, New Orleans, LA,

Endothelial Transcription.

2000 Speaker, Cardiovascular Grand Rounds, Saint Elizabeth’s Hospital, Boston, MA.

Identification of Novel Transcriptional Mediators of Vascular Development and

Angiogenesis.

2001 Speaker, NPACE Boston National Primary Care Conference, Boston MA, Treatment

of Dyslipidemias.

2001 Update On Primary and Secondary Prevention of Coronary Heart Disease. Update

in Internal Medicine CME Course, Boston, MA.

2002 Optimizing Lipid Lowering: Utilizing the Most Recent Therapies in Getting Patients to

Goal. CME Course Cambridge, MA

2002 Emerging Science of Lipid Management: Treatment of Acute Coronary Syndromes.

CME Course, Boston, MA.

2003 Update On Primary and Secondary Prevention of Coronary Heart Disease. Update

in Internal Medicine CME Course, Boston, MA.

2003 Grand Rounds Presentation “Prevention of Coronary Heart Disease” Lemuel

Shattuck Hospital, Jamaica Plain Boston

2004 Boston Angiogenesis Meeting “Angiogenesis: Targeting Transcription Factors”

2003 Harvard Medical School Pri-Med CME conference. “Treatment of Hyperlipidemia:

New Targets.

2004 Boston University School of Medicine; Core Curriculum in Adult Primary Care

Medicine. “Optimizing Treatment Strategies for Primary and Secondary

12

Prevention of Coronary Heart Disease.

2005 Harvard CME LiveMed Conference Mexico City, Mexico

“Hyperlipidemia: New Targets and Management”

2005 Harvard Medical School CME Course Anaheim California “Judicious Use of

Diagnostic Tests in Cardiovascular Disease”

2005 Embryonic Stem Cells; Hype or Hope. American Heart Association National

Meeting, Dallas, Texas, Oral Presentation

2005 “Hyperlipidema; an Update on Diagnosis and Treatment” Harvard CME program

2005 “Metabolic Syndrome” CME conference, Princetion, New Jersey

2004 Keystone Symposium, Invited Spearker, “Molecular Biology of the Vasculature”

“The Role of Ets-1 in AngII-induced Vascular Inflammation and Remodeling”

2006 Medical Grand Rounds, Division of Cardiology, Emory School of Medicine, Atlanta

Georgia. “Angiogenesis and inflammation: targeting transcription factors”

2006 Vascular Biology Seminar, Department of Systems Biology, Tokyo University

Tokyo, Japan “Regulation of Vascular Inflammation and Remodeling; Targeting

Transcription factors.’

2007 Harvard Nutrition and Metabolism Seminar, Athens, Greece. Treatment of

Hyperlipidemia and Hypertension; Lifestyle and Pharmacological Approaches

2007 Sarnoff Endowment for Cardiovascular Research Symposium. Washington, D.C.

Invited Speaker “Vascular Inflammation: Targeting Transcription Factors”

2007 The role of ETS factors in the regulation of vascular inflammation” Vascular Biology

Research Talk. Case Western University, Cardiology Division

2008 “Vascular Inflammation and Remodeling: Targeting Transcription Factors” Medical

Grand Rounds. Case Western University.

2008 Speaker; Gordon Conference, Angiotensin II, Ventura CA “The Role of ETS factors

in Vascular Inflammation and Remodeling”

13

2008 Primary and Secondary Prevention of Coronary Heart Disease

Grand Rounds. Columbia University St. Lukes Hospital

2009 Vascular Inflammation: Targeting Transcription factors” National Institutes of Aging

Baltimore, Maryland Sponsor: Dr. Edward Lakatta.

2010 The Role of ERG in Endothelial Differentiation of Embryonic Stem Cells.

Division of Cardiovascular Diseases, NHLBI/NIH, Bethesda, Maryland

2010 Discussion Leader: Endothelial Cell Specific Signaling Pathways

Gordon Conference “Endothelial Cell Phenotypes in Health and Disease”

University of New England, Biddeford, Maine.

Report of Clinical Activities:

A. Licensure 1990 Massachusetts Medical License # 71658 B. Practice Activities

1. Description of Clinical Practice: The major focus of my clinical practice is preventive cardiology. The practice is based in the Shapiro Clinical Center of the Beth Israel Deaconess Medical Center.

2. Patient load: The patient population consists of patients with a variety of lipid disorders and those at risk for or who have established heart disease. Treatment approaches used include the use of a variety of medications such as lipid lowering medications and a focus on lifestyle modifications.

3. Clinical contributions: As the Director of Preventive Cardiology, I teach residents and fellows in the management of patients from a preventive standpoint. We have also developed a Prevention training course that allows other clinicians to develop lipid clinics within their practices.

4. Inpatient duties: Attend on General Cardiology and Cardiology Consult services.

5. Participate as regular Reader of Electrocardiograms

C. Clinical Innovations

14

As the Director of Preventive Cardiology I developed a multidisciplinary training program to allow Cardiology and Internal Medicine practice groups in Massachusetts develop on site Preventive Cardiology programs consisting of a team of practitioners including a physician, cardiovascular nurse, and dietician. The training course was conducted for two days at Beth Israel Deaconess Medical Center followed by an on-site visit at the Internal Medicine or Cardiology practice site.

III BIBLIOGRAPHY.

Original Reports:

1. Shur BD, Oettgen P, Bennet D. UDPgalactose inhibits blastocyst formation in the mouse.

Developmental Biology. 1979; 73:178-81. 2. Steinhart WL, Busch JS, Oettgen JP, Howland JL. Sphingomyelin metabolism during

infection of human fibroblasts by hsv 1. Intervirology. 1984; 21:70-76. 3. Oettgen P, Antonarakis SE, Karathanasis SK. PvuII polymorphism upstream to the human

ApoCIII gene. Nucleic Acids Research. 1986; 14:5571. 4. Oettgen P, Antonarakis SE, Karathanasis SK. BglII polymorphism downstream to the

human apolipoprotein AIV gene. Nucleic Acids Research. 1986; 14:7138. 5. Karathanasis SK, Oettgen P, Haddad IA, Antonarakis SE. Structure, evolution, and

polymorphisms of the human apolipoprotein A4 gene. Proc. Nat. Acad. Sci. 1986; 83:8457-8461.

6. Antonarakis SE, Oettgen P, Chakravati A, Halloran SL., Hudson RR, Feisee, L,

Karathanasis SK. DNA polymorphism haplotypes of the human apolipoprotein APOA1-APOC3-APOA4 gene cluster. Human Genetics. 1988; 80:265-273.

7. Oettgen P, Ginsburg GS, Horowitz GL, Pasternak RC. Hypercholesterolemia: The impact of hypothyroidism. Am J Card 1994; 73:955-957.

8. Lopez M, Oettgen P, Akbarali Y, Dendorfer U, Libermann TA. ERP, a new member of the

ets transcription factor/oncoprotein family: Cloning, characterization, and differential expression during B lymphocyte development. Mol Cell Biol. 1994; 14:3292-3309.

9. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6

gene mediate induction by prostaglandins, cyclic AMP, and LPS. Mol Cell Biol. 1994; 14:4443-4454.

10. Dendorfer U, Oettgen P, and Libermann TA. Interleukin-6 gene expression by

prostaglandins and cyclic AMP is mediated by multiple regulatory elements. Amer. J. Therapeutics 1995; 2:1-6

11. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echo-

facilitated early cardioversion from atrial fibrillation: a 4.5 year experience. J Am Coll Card 1995; 25:1354-61.

15

12. Manning WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of

residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Int Med: 1995; 155:2193-7.

13. Oettgen P, Ginsburg GS. Cardiac rehabilitation: Implementing a four-phase wellness/risk

reduction program. J. Crit. Ill. 1996; 11:710-719. 14. Oettgen P, Akbarali Y, Boltax J, Best J, Kunsch C, and Libermann TA. Characterization of

NERF, a novel transcription factor related to the Ets factor Elf-1. Mol. Cell. Biol. 1996; 16:5091-5106

15. Akbarali Y, Oettgen P, Boltax J, Liberman TA. ELF-1 Interacts with and transactivates the

IgH enhancer p site. J. Biol. Chem 1996; 271:26007-26012. 16. Oettgen P, Alani RM, Barcinski MA, Brown L, Akbarali Y, Boltax J, Kunsch C, Munger K,

Libermann TA. Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol. Cell. Biol. 1997; 17:4419-4433.

17. Oettgen, P, Carter KC, Augustus M, Barcini M, Boltax J, Kunsch C, Libermann TA. The

Novel Epithelial-Specific Ets Transcription Factor Gene ESX Maps to Human Chromosome q32.1. Genomics 1997; 445(2):456-457.

18. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K.

Adenovirus-mediated Fas ligand gene transfer inhibits neointima formation and diminishes immune surveillance of the vessel wall. Proc. Nat. Acad. Sci. 1998; 95:1213-1217.

19. Oettgen P, Barcinski M, Akbarali Y, Boltax J, Libermann TA. Genomic organization of the

human ELF3 (ESE-1/ESX) gene, a member or the Ets transcription factor family, and identification of a functional promoter. Genomics 1999; 55: 358-362

20. Iljin K, Dube A, Oettgen P, Alitalo,K. Role of the Ets factors in the activity and endothelial

cell specificity of the mouse Tie1 gene promoter. FASEB Journal 1999; 13:377-386. 21. Dube A, Akbarali Y, Boltax J, Sato T, Libermann TA, Oettgen P. Role of the Ets factor

NERF in regulation of the vascular specific Tie 2 gene. Circulation Research. 1999; 84:1177-1185.

22. Oettgen P, Kas K, Dube A, Gu X, Grall F, Thamrongsak U, Akbarali Y, Finger E, Boltax J,

Endress G, Munger K, Kunsch C, Libermann T. Characterization of ESE-2, a novel ESE-1 related Ets transcription factor, that is restricted to glandular epithelium and differentiated keratinocytes. Journal of Biol. Chem. 1999; 274(41):29439-29452.

23. Kas K, Finger E, Grall F, Gu X, Akbarali Y, Boltax J, Oettgen P, Kapeller R, Libermann T. ESE-3, a novel member of an epithelial-specific ETS transcription factor subfamily, demonstrates different target gene specificity from ESE-1. J Biol Chem. 2000; 275(4):2986-2998.

24. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Grall F, Dube A, Brown L, Kas K,

Endress G, Kunsch C, Libermann T. PEDF, a Novel prostate-epithelium specific ETS

16

transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 2000; 275(2)1216-1225.

25. Rudders S, Gaspar J, Madore R, Voland C, Grall F, Patel A, Pellacani A, Perrella M,

Libermann T, Oettgen P. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kB to regulate the inducible nitric oxide gene expression. J Biol Chem 2001; Vol. 276; 3302-3309.

26. Dube A, Thai A, Gaspar J, Rudders S, Libermann TA, Iruela-Arispe L, Oettgen P. ELF-1 is a transcriptional regulator of the Tie2 gene during vascular development. Circulation Research. 2001; 88:237-244.

27. Shin B, Gu X, Akbarali Y, Weiss A, Boltax J, Oettgen P, Libermann TA. Tel-2, a novel transcriptional repressor related to the Ets factor TEL/ETV-6. J Biol. Chem. 2001; Vol 276 (12) 9427-36.

28. Oettgen P. Transcriptional Regulation of Vascular Development. Circulation Research. 2001, 89:380-388.

29. Tsai JC, Zhang J, Minami T, Voland C, Shao S, Yi X, Lassalle P, Oettgen P, Aird WC. Cloning and Characterization of the Human Lung Endothelial Cell-Specific Molecule-1 Promoter. J. Vasc. Research 2002;39:148-59.

30. Christensen RA, Fujikawa K, Madore R, Oettgen P, Varticovski L. NERF2, a member of the Ets family of transcription factors, is induced by hypoxia and upregulates the expression of Tie2. J. Cell. Biochem. 2002;85(3):505-15.

31. Gaspar J, Thai S, Voland C, Dube A, Libermann TA, Iruela-Arispe ML, and Oettgen P. Opposing Functions of Ets Factors NERF and ELF-1 in Regulation of Tie Genes During Chicken Blood Vessel Development ATVB 2002;22:1106-1112.

32. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, Gaspar J, Goldring MB, Goldring SR, Oettgen P Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by TNF-a. Ann Rheum Dis. 2003;62(2):100-7.

33. Grall F, Gu X, Tan L, Cho JY, Inan MS, Pettit AR, Thamrongsak U, Choy BK, Manning C, Akbarali Y, Zerbini L, Rudders S, Goldring SR, Gravallese EM, Oettgen P, Goldring MB, Libermann TA. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum. 2003 May;48(5):1249-60.

34. Laham RJ, Oettgen P. Bone marrow transplantation for the heart: fact or fiction? Lancet. 2003 Jan 4;361(9351):11-2.

35. Flt-1(VEGFR-1)-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids Richard C. Bates, Jeffrey D. Goldsmith, Robin E. Bachelder, Courtney Brown, Masabumi Shibuya, Oettgen P, and Arthur M. Mercurio. Current Biology 2003;13(19):1721-7.

17

36. Brown C, Gaspar J, Pettit A, Lee R, Gu X, Wang H, Manning C, Voland C, Goldring SR, Goldring MB, Libermann TA, Gravalllese EM, Oettgen P. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem. 2004; 279(13):12794-803.

37. Cho JY, Akbarali Y, Zerbini LF, Gu X, Boltax J, Wang Y, Oettgen P, Zhang DE, Libermann TA.Isoforms of the Ets transcription factor NERF/ELF2 physically interact with AML1 and mediate opposing effects on AML1 mediated transcription of the B cell-specific blk gene. J Biol Chem. 2004; 79(19):19512-22.

38. Shie JL, Wu G, Wu J, Liu FF, Laham RJ, Oettgen P, Li J. RTEF-1, a novel transcriptional stimulator of VEGF in hypoxic endothelial cells. J Biol Chem. 2004; 279(24):25010-6.

39. Wang H, Fang R, Cho JY, Libermann TA, Oettgen P. Positive and Negative Modulation of the Transcriptional Activity of the ETS Factor ESE-1 through Interaction with p300, CREB-binding Protein, and Ku 70/86. J Biol Chem. 2004 11;279(24):25241-50.

40. Himes N, Min J, Lee R, Brown C, Shea J, Huang X, Xiao Y, Morgan JP, Brustein D, Oettgen P. In Vivo MRI of Embryonic Stem Cells in a Mouse Model of Myocardial Infarction. MRM 2004; 52:1214-19.

41. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005 115(2):339-47.

42. Grall FT, Prall WC, Wei W, Gu X, Cho JY, Choy BK, Zerbini LF, Inan MS, Goldring SR, Gravallese EM, Goldring MB, Oettgen P, Libermann TA. The Ets transcription factor ESE-1 mediates induction of the COX-2 gene by LPS in monocytes. FEBS J. 2005 272(7):1676-87.

43. Zhan Y, Brown C, Maynard E Anshelevich A, Ni W, Ho I, and Oettgen P. Ets-1 is a critical

regulator of angiotensin II mediated vascular inflammation and remodeling. J Clin Invest. 2005 115(9):2508-2516.

44. Ijiri K, Zerbini LF, Peng H, Correa RG, Lu B, Walsh N, Zhao Y, Taniguchi N, Huang XL, Otu

H, Wang H, Wang JF, Komiya S, Ducy P, Rahman MU, Flavell RA, Gravallese EM, Oettgen P, Libermann TA, Goldring MB. A Novel Role for GADD45beta as a Mediator of MMP-13 Gene Expression during Chondrocyte Terminal Differentiation. J Biol Chem. 2005 280(46):38544-55

45. Huang X, Brown C, Ni W, Maynard E, Rigby AC, Oettgen P. Critical role for the Ets

transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107:3153-3160.

46. Oettgen P. Which lipid parameters are prognostic indicators of cardiovascular disease in

women? Nature Clinical Practice Endocrinology and Metabolism. 2006; 2(4): 190-1.

47. Min, Jiang-Yong, Huang X, Oettgen P, Morgan JP. Homing of intravenously infused embryonic stem cell-derived cells to injured hearts after myocardial infarction. J Thorac Cardiovasc Surg. 2006;131(4):889-897.

18

48. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, and Mercurio AM.

Reciprocal Regulation of RhoC as a Prognostic Marker of Colon Carcinoma. Oncogene. 2006 25(52):6959-67

49. Oettgen P, Boyle AJ, Schulman SP, Hare JM. Cardiac Stem Cell Therapy. Need for

Optimization of Efficacy and Safety Monitoring. Circulation. 2006 25;114(4):353-8.

50. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step Circulation. 2006 25;114(4):339-52.

51. Boyle AJ, Schulman SP, Hare JM, Oettgen P. Is stem cell therapy ready for patients? Stem

Cell Therapy for Cardiac Repair. Ready for the Next Step. Circulation. 2006 25;114(4):339-52.

52. Min J, Xiang M, Wang J, Kaplan E, Oettgen P, Lipsitz L, and Morgan J. Anti-apoptotic effect of implanted embryonic stem cell-derived early-differentiated cells in aging rats after myocardial infarction. J Gerontol A Biol Sci Med Sci. 2006 61(12):1219-27.

53. Oettgen P. Regulation of vascular inflammation and remodeling by ETS factors. Circ Res.

2006 99(11):1159-66.

54. Okada Y, Yano K, Jin E, Funahashi N, Kitayama M, Doi T, Spokes K, Beeler DL, Shih S, Okada H, Danilov TA, Maynard E, Minami T, Oettgen P, and Aird WC. A 3-KB fragment of the human Robo4 promoter directs cell type-specific expression in endothelium. Circ Res. 2007 100(12):1712-22.

55. Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P. Ets-1 is a critical transcriptional

regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ Res. 2007 Nov 9;101(10):985-94

56. Peng H, Tan L, Osaki M, Zhan Y, Ijiri K, Tsuchimochi K, Otero M, Wang H, Choy BK, Grall FT, Gu X, Libermann TA, Oettgen P, Goldring MB.ESE-1 is a potent repressor of type II collagen gene (COL2A1) transcription in human chondrocytes.J Cell Physiol. 2008 215(2):562-73.

57. Nikolova-Krstevski V, Bhasin M, Otu HH, Libermann TA, Oettgen P. Gene expression

analysis of embryonic stem cells expressing VE-cadherin (CD144) during endothelial differentiation. BMC Genomics. 2008 9(1):240.

58. Okada Y, Jin E, Nikolova-Krstevski V, Yano K, Liu J, Beeler D, Spokes K, Kitayama M,

Funahashi N, Doi T, Janes L, Minami T, Oettgen P, Aird WC. A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo. Blood. 2008

59. Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, Bischoff J.

Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res. 2008;103:194-202.

19

60. Komi Y, Suzuki Y, Shimamura M, Kajimoto S, Nakajo S, Masuda M, Shibuya M, Itabe H,

Shimokado K, Oettgen P, Nakaya K, Kojima S. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin. Cancer Sci 2009 100(2):269-77

61. Yuan L, Nikolova-Krstevski V, Zhan Y, Kondo M, Bhasin M, Varghese L, Yano K, Carman

CV, Aird WC, Oettgen P. Antiinflammatory effects of ETS factor ERG in endothelial cells are mediated through transcriptional repression of the interleukin-8 gene. Cir Res. 2009 104(9):1049-57.

62. Zhan Y, Yuan L, Oettgen P. Alterations in transcriptional responses associated with

vascular aging. J Inflamm (Lond). 2009 6:16.

63. Oettgen P. Functional redundancy of Ets1 and Ets2. Blood (2009) 114:934-5.

64. Song H, Suehiro JI, Kanki Y, Kawai Y, Inoue K, Daida H, Yano K, Ohashi T, Oettgen P, Aird WC, Kodama T, Minami T. A critical role for GATA3 in mediating Tie2 expression and function in large vessel endothelial cells. J Biol Chem. 2009 284(42):29109-24.

65. Jin E, Ju Liu, Jun-ichi Suehiro, Yoshiaki Okada, Lei Yuan, Vesna Nikolova-Krstevski,

Kiichiro Yano, Lauren Janes, David Beeler, Katherine C. Spokes, Erzsébet Regan, Oettgen P, Takashi Minami, William C. Aird. Differential role for ETS, CREB and EGR binding sites in mediating VEGF receptor 1 expression in vivo. Blood 2009 Dec 24;114(27):5557-66.

66. Nikolova-Krstevski V, Yuan L, Le Bras A, Virjayaraj P, Kondo M, Gebauer I, Bhasin M,

Carman C, Oettgen P. ERG is required for the differentiation of embryonic stem cells along the endothelial lineage. BMC Developmental Biology 2009 9(1):72

67. Oettgen P. The role of Ets factors in tumor angiogenesis. J Oncol. 2010:767384.

68. Le Bras A, Vijayaraj P, Oettgen P. Molecular mechanisms of endothelial differentiation.

Vasc Med. 2010 Jul 9. [Epub ahead of print]

69. Harris TA, Yamakuchi M, Kondo M, Oettgen P, Lowenstein CJ. Ets-1 and Ets-2 Regulate the Expression of MicroRNA-126 in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2010 Jul 29. [Epub ahead of print]

70. Zhan Y, Yuan L, Kondo M, Oettgen P. The counter-regulatory effects of ESE-1 during

Angiotensin II-mediated vascular inflammation and remodeling Am J Hypertension (in press)

Textbook Reviews:

1. Oettgen P, Douglas PS. Coronary artery disease in women: Diagnosis and prevention.

Advances in Internal Medicine 1994; 39:467-484.

2. Oettgen P. Primary and Secondary Prevention of Coronary Heart Disease in Core Curriculum in Primary Care 1998; Editor M. Rees.

3. Tuck CH, Oettgen P. Disorders of Lipid Metabolism. 2002 (Connolly Graduate Medical

Education).

20

4. Oettgen P. Transcriptional Regulation of Angiogenesis 2002; in “Angiogenesis and Direct

Myocardial Revascularization.”, Humana Press Editors Laham RJ, Baim DS

5. Oettgen P. Transcriptional Networks and Endothelial Lineage 2004 in “Endothelial Cell Phenotypes in Health and Disease” Dekker; Editor William Aird.

6. Tuck CH, Oettgen P. Disorders of Lipid Metabolism. 2004 (Connolly Graduate Medical

Education).

7. Oettgen P. Transcriptional Networks and Endothelial Lineage. 2005 Chapter 17 in “Endothelium in Health and Disease.”

8. Oettgen P. Coupling; The Role of Ets Factors in “Endothelial Biomedicine” 2007 edited by

Aird WC Cambridge University press.

9. Oettgen P. Treatment of Hyperlipidemia and Hypertension; Lifestyle and Pharmacological Approaches. In “Nutrition and Metabolism” Chapter 15 edited by Christos Mantzoros Humana Press 2009

Patents and Provisional Applications 1. United States Patent 6,869,929 Oettgen P. et al. “Targeting transcription factors for treating inflammation and other diseases” 2. United States Patent 6,960,444 Oettgen P. et al. Transcriptional Mediators of Blood Vessel Development and Endothelial Differentiation” 3. Provisional Patent Application (Filed 11/6/06) “Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases. 4. Provisional Patent Application (Filed 11/6/06) Identification and use of small molecules to modulate ESE-1 transcription factor function and to t reat ESE-1 transcription factor associated diseases. 5. Provisional Patent Application (Filed 11/6/06) “Identification and use of small molecules to modulate PDEF transcription factor function and to treat PDEF transcription factor associated diseases. Companies Founding member of Karyon Therapeutics, a company designed to target members of ETS transcription factor family in a wide variety of diseases. Abstracts 1. Goldring MB, Peng H, Ijiri K, Zhan, Y, Grall FT, Tsuchimochi K, Bierbaum BE, Gu X,

Libermann TA, Oettgen P. ESE-1 inhibits COL2A1 promoter activity via Sox9 and CBP. Matrix Biology, 25: S90-S90 Suppl. S 2006

21

2. Ni W., Zhan Y., He H., Maynard E., Balschi JA, Oettgen P. Ets-1 is a critical transcriptional

regulator of reactive oxygen species and p47phox gene expression in response to Angiotensin II. Circulation Research 2007 101(10):985-94.

3. Nugent S, Harris P, Zhu X, Cheng S, Lee HG, Perry G, Oettgen P, Smith M, Castellani R.

CD3 In Lewy Pathology: Does The Abnormal Recall of Neuro-developmental Process UnderlineParkinsonʼs Disease. Journal of Neuropathology and Experimental Neurology, 68 (5): 556-557

Narrative Report: Over the past twenty years I have been active in basic research, clinical activities, teaching, and administration. I have devoted approximately 65 percent of my time to basic research, with a predominant focus on the role of selected transcription factors in regulating vascular inflammation, angiogenesis, and blood vessel development. Clinically, I have served in the role of Director of Preventive Cardiology (15%), an outpatient prevention program directed at treating patients with a variety of lipid disorders and other cardiovascular risk factors for primary and secondary prevention of cardiovascular disease. In addition, I have served as a Cardiology attending on the inpatient ward services. My role as teacher (5%) has included the teaching of medical students, resident, and cardiology fellows in preventive cardiology, Finally my role in administration (15%) has included serving as Director of Preventive Cardiology, the Associate Chief of the Division of Molecular and Vascular Medicine, and as Special Advisor at the National Heart, Lung, and Blood Institute (NHLBI), in the Division of Cardiovascular Diseases. With respect to basic research, I received an NIH Physician-Scientist award in 1995, and started an independent laboratory at Beth Israel Deaconess Medical Center at the Harvard Institutes of Medicine in 1997 with a specific focus on the role of members of the ETS transcription factor in regulating vascular specific genes. More importantly we identified important roles for selected members of this family in regulating vascular inflammation, angiogenesis, endothelial differentiation, and vascular development. The lab has been supported by 5 independent R01 grants from the NIH, an Established Investigator Award from the American Heart Association, and industry support from Johnson and Johnson. As teacher, I have had a longstanding interest in training medical students, medical residents, endocrine and cardiology fellows in Preventive Cardiology, who rotate through the Cardiovascular Health and Lipid Center that I direct in the Shapiro Clinical Center. I have also participated in a variety of CME activities at Beth Israel Deaconess Medical Center and Harvard Medical School with contributions in the area of Preventive Cardiology. From an administrative standpoint, I have served as the Director of Preventive Cardiology since 1997, and as the Associate Chief of the Division of Molecular and Vascular Medicine since 2008. My role as Associate Chief includes mentoring young faculty with regarding their basic science career development, recruitment of new faculty to the Center for Vascular Biology Research (CVBR), and serving as Chair for our annual CVBR, retreat. At the national level I have a position at the NHLBI as a special advisor to their Vascular Biology and Hypertension branch. I travel once a month to the NIH to advise them on the development of new initiatives in vascular biology research.